GC 502
Alternative Names: GC-502Latest Information Update: 26 Feb 2024
At a glance
- Originator Gracell Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 22 Feb 2024 Gracell Biotechnology has been acquired by AstraZeneca
- 12 May 2022 Efficacy and adverse events data from a phase I trial in B Cell acute lymphoblastic leukemia released by Gracell Biotechnology
- 08 Apr 2022 Adverse event and pharmacodynamics data from a phase I trial in B Cell acute lymphoblastic leukemia presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)